Recently, SH-1028 was evaluated in a phase III trial (NCT04239833), comparing its efficacy and safety to first- and second-generation EGFR-TKIs as a first-line treatment in advanced EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.